In a blow to the pharmaceutical industry, the California Supreme Court ruled that Novartis (NVS) can be held responsible for injuries blamed on versions of its drugs made by generic manufacturers.

The ruling contradicted most decisions in courts elsewhere around the country and, importantly, may create new liability for drug makers, which could be sued in California for failing to warn patients about the risks posed by generic versions of their medicines.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy